Geron Corporation - Common Stock (GERN)
Frequently Asked Questions About Geron Corporation - Common Stock (GERN)
How does Geron Corporation fund its operations?
Geron Corporation funds its operations through a combination of public offerings, partnerships, and collaborations with other pharmaceutical companies and research organizations. They also may receive grants or funding from governmental and non-governmental organizations to support their research and development initiatives.
How does Geron's pipeline look?
Geron's pipeline focuses primarily on hematologic malignancies, with imetelstat at the forefront. The company is actively evaluating additional indications for imetelstat and may introduce new candidates in the future as part of its ongoing research and development initiatives.
Is Geron Corporation publicly traded?
Yes, Geron Corporation is publicly traded under the ticker symbol 'GERN' on the Nasdaq Stock Market. Being publicly traded allows the company to access capital markets to finance its research and development activities.
What are hematologic malignancies?
Hematologic malignancies are cancers that affect the blood, bone marrow, and lymphatic system, including types such as leukemia, lymphoma, and myeloma. These cancers disrupt the normal production of blood cells and can have serious implications for a patient's overall health.
What are the financial trends for Geron Corporation?
As of October 2023, Geron Corporation's financial trends have reflected the early-stage nature of its clinical development, with investments primarily allocated to research and clinical trials. The company's financial health can be assessed through its balance sheet, revenue from potential partnerships, and stock performance.
What are the potential benefits of imetelstat for patients?
Imetelstat offers potential benefits for patients with hematologic malignancies by targeting the underlying biology of cancer cells, which can lead to improved outcomes, including increased survival rates and better quality of life by halting disease progression.
What are the potential side effects of imetelstat?
As with any investigational drug, imetelstat may have side effects, which can include fatigue, cytopenias, and liver enzyme elevation, among others. The clinical trials are designed to monitor patients for these potential side effects and assess the drug's overall safety profile.
What challenges does Geron Corporation face?
Geron Corporation faces several challenges typical in the biotech industry, including the need for successful clinical trial outcomes, regulatory approvals, competition from other therapies, and the ability to secure funding for ongoing research and development.
What does Geron Corporation do?
Geron Corporation is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for hematologic malignancies and solid tumors. The company's lead product candidate, imetelstat, is a telomerase inhibitor designed to treat cancer by targeting the underlying mechanisms of tumor growth.
What is Geron Corporation's mission?
Geron Corporation's mission is to transform the treatment landscape for patients with unmet medical needs in the area of cancer. The company is committed to developing novel therapies that target the biology of cancer, aiming to provide better outcomes and enhance the quality of life for patients.
What is imetelstat?
Imetelstat is Geron's lead candidate, a telomerase inhibitor that specifically targets and inhibits telomerase activity, which is often upregulated in malignant cells. This makes it a potentially effective treatment for certain types of cancer, such as myelofibrosis, where telomerase plays a crucial role in tumor growth.
What is the current status of imetelstat in clinical trials?
As of October 2023, imetelstat is undergoing clinical trials to evaluate its efficacy and safety in patients with hematologic malignancies, including myelofibrosis and other forms of blood cancers. The trials aim to determine the drug's potential to improve survival rates and quality of life for patients.
What is the significance of telomerase in cancer?
Telomerase is an enzyme that helps maintain the length of telomeres, the protective caps on the ends of chromosomes. In many cancer cells, telomerase is abnormally active, allowing these cells to divide indefinitely. Targeting telomerase can therefore limit the growth of tumors and serves as a promising therapeutic strategy.
What partnerships has Geron Corporation formed?
Geron has engaged in strategic collaborations with various pharmaceutical companies and research institutions to further its drug development efforts. These partnerships often focus on shared resources, expertise, and financial support to bring innovative therapies to market more efficiently.
What role does the FDA play in Geron's drug development?
The U.S. Food and Drug Administration (FDA) is a regulatory body that reviews and approves new drugs and therapies developed by companies like Geron. The FDA ensures that new treatments are safe and effective based on sufficient scientific evidence, playing a crucial role in bringing innovative therapies to market.
When was Geron Corporation founded?
Geron Corporation was founded in 1990, making it one of the early entrants into the biotechnology field focusing on telomerase and its role in cancer progression, which has remained a core area of interest for the company since its inception.
Where is Geron Corporation located?
Geron Corporation is headquartered in Menlo Park, California. The company's location in Silicon Valley positions it well within a vibrant ecosystem of innovation, talent, and collaboration in the biotechnology and pharmaceutical sectors.
Who are the key people at Geron Corporation?
The leadership team at Geron Corporation includes experienced professionals in the biotechnology and pharmaceutical industries. This typically comprises a CEO, CFO, Chief Medical Officer, and other key executives who guide the company's strategic direction, research, and development efforts.
What is the current price of Geron Corporation - Common Stock?
The current price of Geron Corporation - Common Stock is 1.590
When was Geron Corporation - Common Stock last traded?
The last trade of Geron Corporation - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Geron Corporation - Common Stock?
The market capitalization of Geron Corporation - Common Stock is 808.94M
How many shares of Geron Corporation - Common Stock are outstanding?
Geron Corporation - Common Stock has 508.77M shares outstanding.